Ensign Peak Advisors’s Nurix Therapeutics NRIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.63M | Hold |
230,828
| – | – | ﹤0.01% | 818 |
|
|
2025
Q1 | $2.74M | Sell |
230,828
-143,845
| -38% | -$1.71M | 0.01% | 797 |
|
|
2024
Q4 | $7.06M | Buy |
374,673
+194,673
| +108% | +$3.67M | 0.01% | 558 |
|
|
2024
Q3 | $4.04M | Buy |
180,000
+144,356
| +405% | +$3.24M | 0.01% | 701 |
|
|
2024
Q2 | $744K | Sell |
35,644
-44,263
| -55% | -$924K | ﹤0.01% | 1461 |
|
|
2024
Q1 | $1.17M | Hold |
79,907
| – | – | ﹤0.01% | 1211 |
|
|
2023
Q4 | $825K | Hold |
79,907
| – | – | ﹤0.01% | 1486 |
|
|
2023
Q3 | $628K | Hold |
79,907
| – | – | ﹤0.01% | 1510 |
|
|
2023
Q2 | $798K | Hold |
79,907
| – | – | ﹤0.01% | 1420 |
|
|
2023
Q1 | $710K | Hold |
79,907
| – | – | ﹤0.01% | 1505 |
|
|
2022
Q4 | $877K | Sell |
79,907
-7,060
| -8% | -$77.5K | ﹤0.01% | 1269 |
|
|
2022
Q3 | $1.13M | Buy |
86,967
+2,170
| +3% | +$28.3K | ﹤0.01% | 1004 |
|
|
2022
Q2 | $1.07M | Hold |
84,797
| – | – | ﹤0.01% | 1080 |
|
|
2022
Q1 | $1.19M | Buy |
84,797
+79,907
| +1,634% | +$1.12M | ﹤0.01% | 1103 |
|
|
2021
Q4 | $142K | Buy |
4,890
+4,091
| +512% | +$119K | ﹤0.01% | 2001 |
|
|
2021
Q3 | $24K | Hold |
799
| – | – | ﹤0.01% | 1846 |
|
|
2021
Q2 | $21K | Hold |
799
| – | – | ﹤0.01% | 1818 |
|
|
2021
Q1 | $25K | Hold |
799
| – | – | ﹤0.01% | 1822 |
|
|
2020
Q4 | $26K | Hold |
799
| – | – | ﹤0.01% | 1845 |
|
|
2020
Q3 | $28K | Buy |
+799
| New | +$28K | ﹤0.01% | 1735 |
|